These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 21394100

  • 1. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ, Vega F, Medeiros LJ.
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [Abstract] [Full Text] [Related]

  • 2. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
    Drakos E, Atsaves V, Schlette E, Li J, Papanastasi I, Rassidakis GZ, Medeiros LJ.
    Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ.
    Clin Cancer Res; 2007 Jun 01; 13(11):3380-7. PubMed ID: 17545546
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T, Wang J, Chen X, Meng X, Song X, Lu Z, Jiang H, Liu L.
    Tumour Biol; 2010 Aug 01; 31(4):287-95. PubMed ID: 20422343
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM, Bhattacharya S, Johnson LR.
    Apoptosis; 2011 Jan 01; 16(1):35-44. PubMed ID: 20812030
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A, De Preter K, Heukamp L, Thor T, Pajtler KW, Hartmann W, Mittelbronn M, Grotzer MA, Deubzer HE, Speleman F, Schramm A, Eggert A, Schulte JH.
    Neuro Oncol; 2012 Jul 01; 14(7):859-69. PubMed ID: 22591662
    [Abstract] [Full Text] [Related]

  • 10. Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation.
    Pan D, Pan LZ, Hill R, Marcato P, Shmulevitz M, Vassilev LT, Lee PW.
    Br J Cancer; 2011 Sep 27; 105(7):1012-22. PubMed ID: 21863032
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.
    J Natl Cancer Inst; 2009 Nov 18; 101(22):1562-74. PubMed ID: 19903807
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
    Mochizuki H, Goto-Koshino Y, Sato M, Fujino Y, Ohno K, Tsujimoto H.
    Vet Immunol Immunopathol; 2012 Jun 30; 147(3-4):187-94. PubMed ID: 22578852
    [Abstract] [Full Text] [Related]

  • 13. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM, Nugent JK, Zhao X, Irwin MS.
    Oncogene; 2008 Feb 07; 27(7):997-1003. PubMed ID: 17700533
    [Abstract] [Full Text] [Related]

  • 14. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
    Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies-Hill T, Miyake K, Miida T, Pittaluga S, Raffeld M.
    Clin Cancer Res; 2009 Feb 01; 15(3):933-42. PubMed ID: 19188164
    [Abstract] [Full Text] [Related]

  • 15. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H.
    Cancer Biol Ther; 2010 Jun 01; 9(11):936-44. PubMed ID: 20418664
    [Abstract] [Full Text] [Related]

  • 16. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
    Jin L, Tabe Y, Kojima K, Zhou Y, Pittaluga S, Konopleva M, Miida T, Raffeld M.
    Cancer Lett; 2010 Dec 28; 299(2):161-70. PubMed ID: 20850924
    [Abstract] [Full Text] [Related]

  • 17. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
    Wang B, Fang L, Zhao H, Xiang T, Wang D.
    Acta Biochim Biophys Sin (Shanghai); 2012 Aug 28; 44(8):685-91. PubMed ID: 22843172
    [Abstract] [Full Text] [Related]

  • 18. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
    Manfé V, Biskup E, Johansen P, Kamstrup MR, Krejsgaard TF, Morling N, Wulf HC, Gniadecki R.
    J Invest Dermatol; 2012 May 28; 132(5):1487-96. PubMed ID: 22377766
    [Abstract] [Full Text] [Related]

  • 19. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tsuchiya K, Iehara T, Hosoi H.
    Clin Cancer Res; 2009 Jun 15; 15(12):4077-84. PubMed ID: 19509161
    [Abstract] [Full Text] [Related]

  • 20. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
    Tovar C, Higgins B, Kolinsky K, Xia M, Packman K, Heimbrook DC, Vassilev LT.
    Mol Cancer; 2011 May 03; 10():49. PubMed ID: 21539745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.